Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,739.92
(
0.61%
)
US TECH 100
24,179.60
(
0.68%
)
Dow Jones
47,162.97
(
0.46%
)
Brent Oil
99.33
(
1.04%
)
Bitcoin
74,198.55
(
-0.86%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 150574

Monday, 10/15/2012 1:26:04 PM

Monday, October 15, 2012 1:26:04 PM

Post# of 257251
ABT’s HCV results in the null-responder population are off-the-charts superlative; the age of interferon use in HCV may truly be nearing an end. Moreover, ABT did it without using a nuke in the cocktail.

Detailed discussion of these results will have to wait for the PR/presentation at AASLD, but it appears that ABT’s prior boasting of “unprecedented” success in HCV (#msg-68216224) was not unfounded.

p.s. ABT is trading today at an all-time high.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now